Targeted Liposomal Drug Delivery to Monocytes and Macrophages

Kelly, Ciara; Jefferies, Caroline A.; Cryan, Sally‐Ann

doi:10.1155/2011/727241

Cited by 336 publications

(221 citation statements)

References 107 publications

Supporting

Mentioning

214

Contrasting

Unclassified

Order By: Relevance

“…But it has some shortcomings like poor scale-up, cost, short shelf life, and in some cases toxicity and off target effects. To make it long circulatory, shielding with PEG is required, and concept of stealth liposomes has risen out (Kelly et al, 2011).…”

Section: Liposomesmentioning

confidence: 99%

Bisphosphonates: therapeutics potential and recent advances in drug delivery

et al. 2014

View full text Add to dashboard Cite

Context: Bisphosphonates (BPs) are widely used for prevention and treatment of osteoporosis. BPs are known as gold standard for osteoporosis (OP) treatment due to their positive results in clinical studies. But some serious side effects are associated with BPs like gastrointestinal adverse effect i.e. esophagitis and ulcer of esophagus. Oral bioavailability (BA) of BPs ranges from 0.6 to 1% due to poor absorption through gastrointestinal tract (GIT). Objective: The main objective of this review is to explore the role of novel drug delivery systems (DDSs) for the delivering of BPs and minimizing the drawbacks associated with them. Methods: The current review is focusing on classification, mechanism of action, and limitations of BPs, and is also dwelling on the use of novel DDSs like nanoparticles, liposomes, topical, transdermal systems, implants, bisphosphonate osteotropic DDS (BP-ODDS), microspheres, and calcium phosphate cements (CPCs) for BPs. This review also gives a critically reviewed compilation of the various in vitro and in vivo studies conducted till date. Conclusion: On the basis of the exhaustive literature, it has been found that the novel DDS minimizes the side effects associated with BPs and enhances the BA. The advance drug delivery has a greater impact on reducing the undesirable effects and increasing the BA of BPs.

show abstract

Section: Liposomesmentioning

confidence: 99%

Bisphosphonates: therapeutics potential and recent advances in drug delivery

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The negatively charged lipid was used to prepare anionic liposomal formulations in order to prevent the aggregation of liposomes due to electrostatic repulsion [24,30,31]. Furthermore, it was reported that the presence of negatively charged lipids in liposomes, allows rapid uptake by the reticuloendothelial system [24], while large and positively charged liposomes induce cytokine activation and toxicity and thereby their safety for clinical use is limited [32].…”

Section: Introductionmentioning

confidence: 99%

Comparative Study of PEGylated and Conventional Liposomes as Carriers for Shikonin

Tsermentseli

Kontogiannopoulos

Papageorgiou

et al. 2018

Fluids

View full text Add to dashboard Cite

Abstract:Liposomes are considered to be one of the most successful drug delivery systems.They apply nanotechnology to potentiate the therapeutic efficacy and reduce the toxicity of conventional medicines. Shikonin and alkannin, a pair of chiral natural naphthoquinone compounds, derived from Alkanna and Lithospermum species, are widely used due to their various pharmacological activities, mainly wound healing, antioxidant, anti-inflammatory and their recently established antitumor activity. The purpose of this study was to prepare conventional and PEGylated shikonin-loaded liposomal formulations and measure the effects of different lipids and polyethylene glycol (PEG) on parameters related to particle size distribution, the polydispersity index, the zeta potential, drug-loading efficiency and the stability of the prepared formulations. Three types of lipids were assessed (1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-distearoyl-sn-glycero-3-phospho-rac-(1-glycerol) (DSPG)), separately and in mixtures, forming anionic liposomes with good physicochemical characteristics, high entrapment efficiencies (varying from 56.5 to 89.4%), satisfactory in vitro release profiles and good physical stability. The addition of the negatively charged DSPG lipids to DOPC, led to an increment in the drug's incorporation efficiency and reduced the particle size distribution. Furthermore, the shikonin-loaded PEGylated sample with DOPC/DSPG, demonstrated the most satisfactory characteristics. These findings are considered promising and could be used for further design and improvement of such formulations.

show abstract

“…The reason for the fast clearance of liposomes to the liver is most probably due to the presence of the positively charged DOTAP in the liposome formulation, which could lead to recognition by the macrophages (Kelly et al, 2011). Our theory was that the presence of DTPA on the surface would shield the charge from the blood compartment.…”

Section: Scintigraphic Imaging Studymentioning

confidence: 87%

Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution

Flaten¹,

Chang²,

Phillips³

et al. 2012

Journal of Liposome Research

View full text Add to dashboard Cite

Context: Camptothecin (CPT) represents a potent anticancer drug. Its therapeutic use however is impaired by both drug solubility, hydrolysis and protein interactions in vivo. Use of liposomes as drug formulation approach could overcome some of these challenges.Objective: The objective of this study was to perform a mechanistic study of the incorporation and retention of the lipophilic parent CPT-compound in different liposome formulations using radiolabeled CPT and thus be able to identify promising CPT delivery systems. In this context we also wanted to establish an appropriate mouse tumor model, in vivo scintigraphic imaging and biodistribution methodology for testing the most promising formulation. Materials and methods:CPT retention in various liposome formulations following incubation in buffer and serum was determined. The HT-29 mouse tumor model, 111 In-labeled liposomes as well as 3 H-labeled CPT were used to investigate the biodistribution of liposomes and drug. Results and discussion:The ability of different liposome formulations to retain CPT in buffer was influenced by the lipid concentration and the drug:lipid ratio rather than lipid composition.The tested formulations were cleared from the blood in the following order:CPT-solutionCPT-liposomes 111 In-labeled liposomes, and liposomes mainly accumulated in liver. Conclusion:Lipid composition did not influence CPT retention to the same extent as earlier observed in incorporation studies. The set up for the biodistribution study works well and is suited for future in vivo studies on CPT liposomes. The biodistribution study showed that liposomes circulated longer than free drug, but premature release of drug from liposomes occurred. Further studies to develop formulations with higher retention potential and prolonged circulation are desired.2

show abstract

Targeted Liposomal Drug Delivery to Monocytes and Macrophages

Cited by 336 publications

References 107 publications

Bisphosphonates: therapeutics potential and recent advances in drug delivery

Bisphosphonates: therapeutics potential and recent advances in drug delivery

Comparative Study of PEGylated and Conventional Liposomes as Carriers for Shikonin

Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution

Contact Info

Product

Resources

About